Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein‐1 that are not influenced by the –2518 A→G promoter polymorphism
暂无分享,去创建一个
U. Müller-Ladner | J. Schölmerich | H. Herfarth | A. Schäffler | B. Zietz | C. Büchler | D. Spiegel
[1] J. Damås,et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. , 2004, European heart journal.
[2] K. Kohara,et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.
[3] S. Higuchi,et al. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. , 2003, European journal of pharmacology.
[4] B. Angelkort,et al. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. , 2003, Diabetes care.
[5] M. González-Escribano,et al. MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis. , 2003, Human immunology.
[6] U. Müller-Ladner,et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL‐cholesterol levels in type 2 diabetes , 2003, FEBS letters.
[7] H. Takaishi,et al. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. , 2003, Biochemical and biophysical research communications.
[8] D. Loskutoff,et al. Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. A. Reddy,et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. , 2003, Diabetes.
[10] E. Antman,et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.
[11] C. Hellerbrand,et al. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease , 2003, International Journal of Colorectal Disease.
[12] M. Kakei,et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. , 2003, Journal of diabetes and its complications.
[13] S. Yang,et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] F. Cipollone,et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. , 2002, Diabetes care.
[15] A. Aljada,et al. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. , 2002, Metabolism: clinical and experimental.
[16] Y. Tomino,et al. Urinary levels of monocyte chemoattractant protein‐1 (MCP‐1) and interleukin‐8 (IL‐8), and renal injuries in patients with type 2 diabetic nephropathy , 2002, Journal of clinical laboratory analysis.
[17] Y. Tagawa,et al. Monocyte Chemotactic Protein-1 in the Vitreous of Patients with Proliferative Diabetic Retinopathy , 2001, Ophthalmologica.
[18] Z. Prohászka,et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. , 2001, Atherosclerosis.
[19] Y. Kaneda,et al. Leptin Induces Mitochondrial Superoxide Production and Monocyte Chemoattractant Protein-1 Expression in Aortic Endothelial Cells by Increasing Fatty Acid Oxidation via Protein Kinase A* , 2001, The Journal of Biological Chemistry.
[20] A. Aljada,et al. Nuclear Factor-κB Suppressive and Inhibitor-κB Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?1 , 2001 .
[21] A. Strosberg,et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes , 2001, Molecular and Cellular Endocrinology.
[22] A. Aljada,et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? , 2001, The Journal of clinical endocrinology and metabolism.
[23] J. Schölmerich,et al. Gly15Gly polymorphism within the human adipocyte-specific apM-1gene but not Tyr111His polymorphism is associated with higher levels of cholesterol and LDL-cholesterol in caucasian patients with type 2 diabetes , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[24] K. Matsushima,et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. , 2000, Kidney international.
[25] Y. Hattori,et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. , 2000, Kidney international.
[26] B. Rovin,et al. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. , 1999, Biochemical and biophysical research communications.
[27] B. Rollins,et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.
[28] P. Libby,et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.
[29] E. Appella,et al. Human monocyte chemoattractant protein‐1 (MCP‐1) Full‐length cDNA cloning, expression in mitogen‐stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE , 1989, FEBS letters.